Phase 1 N=70 An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Experienced an Adverse Event During the Study — 46; 21 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=44 A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
Diabetes Mellitus, Type 2
Primary: Number of Participants With Any Clinical Adverse Experience — 18; 16 participants
Phase 1 N=42 SSP-002358 Drug Interaction Study With Omeprazole
Healthy
Primary: Maximum Plasma Concentration (Cmax) for SSP-002358 — 3.89; 4.12 ng/ml
Phase 1 N=30 Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Ciprofloxacin XR — 7805; 7934 ng*h/ml
Phase 1 N=10 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Lymphoma
Primary: Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE) — 10; 6 participants
Phase 1 N=27 A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Leukemia
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 0; 0; 0 percentage of participants
Phase 1 N=180 Bioequivalence of Two Different Capsule Types of Dabigatran
Healthy
Primary: Area Under the Curve 0 to tz (AUC0-tz) of Total Dabigatran — 1147.64; 908.48 ng*hr/mL
Phase 1 N=32 An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment — 0; 0; 0; 1 Number of…
Phase 1 N=24 A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form
Biological Availability
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 1286.00; 1204.00; 1180.00 ng*hr/mL
Phase 1 N=20 A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
Healthy
Primary: Computer Based Objective Cognition Testing (CogState) Detection Speed — 2.6333; 2.5971; 2.6103; 2.5842 Log10 MS
Phase 1 N=68 Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)
Carcinoma · Non-small Cell Lung Cancer
Primary: Metabolic Response Conversion Rate Between 3 and 6 Weeks After Starting Chemotherapy at a Threshold of a 20% Decrease in SUVmean — 10 Participants
Phase 1 N=70 A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
Type 2 Diabetes Mellitus
Primary: Participants With Any Clinical Adverse Experience — 51.9; 61.1 percentage of of participants
Phase 1 N=40 V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
Staphylococcal Infection
Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio
Phase 1 N=21 Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Central Nervous System Diseases
Primary: Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator. — 0; 0; 1; 0 participants
Phase 1 N=41 Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
HIV Infections · Depression
Primary: The Number of Sexual Partners in Unprotected Anal Intercourse Reported at 6 Months Minus the Number Reported at Enrollment. — -2.5; -4 Sexual partners — p=0.9